Focused On-demand Library for Immunoglobulin kappa constant

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P01834

UPID:

IGKC_HUMAN

Alternative names:

Ig kappa chain C region; Ig kappa chain C region AG; Ig kappa chain C region CUM; Ig kappa chain C region EU; Ig kappa chain C region OU; Ig kappa chain C region ROY; Ig kappa chain C region TI

Alternative UPACC:

P01834; A0A075B6H6; A0A087X130

Background:

The Immunoglobulin kappa constant plays a pivotal role in the immune response. It is part of the immunoglobulin light chains, crucial for the formation of antibodies by B lymphocytes. These antibodies are essential for recognizing and eliminating antigens, with the kappa constant region contributing to the antibody's stability and specificity. The protein is encoded by a gene that, when mutated, leads to Immunoglobulin kappa light chain deficiency, a condition marked by the absence of kappa chains.

Therapeutic significance:

Given its fundamental role in humoral immunity, targeting the Immunoglobulin kappa constant could offer novel therapeutic avenues for treating Immunoglobulin kappa light chain deficiency. Enhancing our understanding of this protein's function and its interaction with antigens could pave the way for innovative treatments.